Overview
MNPR market data
Price History
MNPR price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.85 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.40 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $29.18 – $124.82 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $737.9M · P/B 3.17.
Company News
This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For ThursdayBenzinga · Aug 13, 2026, 4:09 PM
Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $128Benzinga · Aug 13, 2026, 2:21 PM
Cantor Fitzgerald Downgrades Monopar Therapeutics to Neutral, Raises Price Target to $119Benzinga · Aug 13, 2026, 11:56 AM
BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $133Benzinga · Aug 12, 2026, 7:48 PM
Monopar Therapeutics Q2 EPS $(0.62) Misses $(0.56) EstimateBenzinga · Aug 12, 2026, 1:32 PM
8-K filing — Monopar Therapeutics (MNPR)SEC EDGAR · Aug 12, 2026, 1:30 PM
HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $125Benzinga · Jul 22, 2026, 3:59 PM
Monopar Therapeutics Begins Rolling Submission Of FDA New Drug Application For ALXN1840 Albumin Tripartite Complex Activator To Treat Wilson DiseaseBenzinga · Jul 22, 2026, 12:02 PM
Monopar Says FDA Grants Rare Pediatric Disease Designation To ALXN1840, Late-Stage Candidate For Treatment Of Wilson DiseaseBenzinga · Jun 30, 2026, 12:05 PM
Monopar Therapeutics To Present New Analyses From Phase 3 FoCus Randomized Clinical Trial Of ALXN1840 At EAN 2026.Benzinga · Jun 26, 2026, 8:15 PM